RxDoctor Payments Data

Marcos de Lima, MD

Hematology & Oncology · Cleveland, OHNPI 1851491195

Payments from drug & device makers

$82,856in general payments, 2019–2025

Across 61 payments — averaging $1358.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$24K
  • Gilead$13K
  • Jazz Pharmaceuticals Inc.$9K
  • Bristol Myers Squibb$8K
  • Pfizer S.a.s.$7K
  • E.r. Squibb & Sons, L.L.C.$6K
  • plus $15K from 9 others
$21,381in research payments, 2019–2025

Across 15 payments — averaging $1425.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$13K
  • AbbVie$8K
  • Bristol Myers Squibb$476

What the payments were for

  • Consulting fees$40,40751%
  • Speaking & faculty fees$29,00136%
  • Travel & lodging$4,3285%
  • Food & beverage$1,8552%
  • Education$4,0655%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer17$24,214
Gilead10$13,262
Jazz Pharmaceuticals Inc.8$8,553
Bristol Myers Squibb7$8,422
Pfizer S.a.s.2$7,497
E.r. Squibb & Sons, L.L.C.2$6,408
AbbVie3$5,802
Daiichi Sankyo Inc.2$3,375
Takeda Pharmaceuticals U.S.A., Inc.1$2,200
Kadmon Pharmaceuticals LLC1$1,536
National Marrow Donor Program2$1,222
Novartis3$152
Johnson & Johnson1$99
Incyte Corporation1$98
Sanofi1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$82,856 in reported general payments places this provider in the 70th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$11,492
Medicare patients
37
Services billed
128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate52$909,333

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$98$909,33352 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →